Novel anti-cancer compounds called Enigmols suppress the growth of human cell lines representing cancers of the prostate, breast, colon, ovary, pancreas, brain and blood, and reduce tumors in three animal studies. In addition, Enigmols did not show side effects at effective doses, according to the research conducted at the Georgia Institute of Technology, Emory University and Wayne State University. The studies were funded by the National Cancer Institute. Collaborators to the research at Wayne State are Professors Eva Schmelz and Paul Roberts.